Diane St Germain1, Worta McCaskill Stevens2, Ann O'Mara2. 1. National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD, 20892, USA. Dstgermain@mail.nih.gov. 2. National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD, 20892, USA.
Abstract
PURPOSE: This study was conducted to describe the portfolio of symptom science research conducted through the community oncology network supported by the US National Cancer Institute during the 12-year period 2008 to 2019. METHODS: The National Cancer Institute conducted a retrospective review of the National Cancer Institute database to identify pediatric and adult symptom management studies that were opened between 2008 and 2019 in the community oncology network and to determine types of studies, accrual patterns, completed studies, and number of publications reporting clinical trial results. RESULTS: The NCI community oncology network conducted 109 symptom studies between 2008 and 2019. The majority of these studies were phase II and III clinical trials. Neurotoxicities were the most frequently occurring symptom studied, with the majority of those focused on neurocognitive impairments. Gastrointestinal symptoms, pain, and fatigue were the next most frequently studied. A variety of interventions were utilized including pharmacologic, behavioral, complementary and alternative medicines, and radiation therapy. Accrual to symptom studies ranged from a low of 896 participants in 2008 to a high of 3468 participants in 2012. The number of open studies ranged from 8 in 2008 to 35 in 2012. CONCLUSIONS: Examining the symptom science portfolio of the NCI community oncology network has identified research gaps and has highlighted the need to focus on a mechanistic understanding of symptoms and phenotyping of patients experiencing cancer and treatment-related symptoms. Subsequently, targeted interventions can be developed to prevent or treat these symptoms.
PURPOSE: This study was conducted to describe the portfolio of symptom science research conducted through the community oncology network supported by the US National Cancer Institute during the 12-year period 2008 to 2019. METHODS: The National Cancer Institute conducted a retrospective review of the National Cancer Institute database to identify pediatric and adult symptom management studies that were opened between 2008 and 2019 in the community oncology network and to determine types of studies, accrual patterns, completed studies, and number of publications reporting clinical trial results. RESULTS: The NCI community oncology network conducted 109 symptom studies between 2008 and 2019. The majority of these studies were phase II and III clinical trials. Neurotoxicities were the most frequently occurring symptom studied, with the majority of those focused on neurocognitive impairments. Gastrointestinal symptoms, pain, and fatigue were the next most frequently studied. A variety of interventions were utilized including pharmacologic, behavioral, complementary and alternative medicines, and radiation therapy. Accrual to symptom studies ranged from a low of 896 participants in 2008 to a high of 3468 participants in 2012. The number of open studies ranged from 8 in 2008 to 35 in 2012. CONCLUSIONS: Examining the symptom science portfolio of the NCI community oncology network has identified research gaps and has highlighted the need to focus on a mechanistic understanding of symptoms and phenotyping of patients experiencing cancer and treatment-related symptoms. Subsequently, targeted interventions can be developed to prevent or treat these symptoms.
Authors: Carolyn Miller Reilly; Deborah Watkins Bruner; Sandra A Mitchell; Lori M Minasian; Ethan Basch; Amylou C Dueck; David Cella; Bryce B Reeve Journal: Support Care Cancer Date: 2013-01-12 Impact factor: 3.603
Authors: Charles S Cleeland; Fengmin Zhao; Victor T Chang; Jeff A Sloan; Ann M O'Mara; Paul B Gilman; Matthias Weiss; Tito R Mendoza; Ju-Whei Lee; Michael J Fisch Journal: Cancer Date: 2013-09-24 Impact factor: 6.860
Authors: Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi Journal: N Engl J Med Date: 2016-07-14 Impact factor: 91.245
Authors: Patsy Yates; Christine Miaskowski; Janine K Cataldo; Steven M Paul; Bruce A Cooper; Kimberly Alexander; Bradley Aouizerat; Laura Dunn; Christine Ritchie; Alexandra McCarthy; Helen Skerman Journal: J Pain Symptom Manage Date: 2015-01-10 Impact factor: 3.612
Authors: M Dodd; S Janson; N Facione; J Faucett; E S Froelicher; J Humphreys; K Lee; C Miaskowski; K Puntillo; S Rankin; D Taylor Journal: J Adv Nurs Date: 2001-03 Impact factor: 3.187
Authors: Leanne Fleming; Kate Randell; Elaine Stewart; Colin A Espie; David S Morrison; Claire Lawless; James Paul Journal: Sleep Date: 2019-03-01 Impact factor: 5.849
Authors: Xin Shelley Wang; Fengmin Zhao; Michael J Fisch; Ann M O'Mara; David Cella; Tito R Mendoza; Charles S Cleeland Journal: Cancer Date: 2014-02-01 Impact factor: 6.860
Authors: Judith A Paice; Russell Portenoy; Christina Lacchetti; Toby Campbell; Andrea Cheville; Marc Citron; Louis S Constine; Andrea Cooper; Paul Glare; Frank Keefe; Lakshmi Koyyalagunta; Michael Levy; Christine Miaskowski; Shirley Otis-Green; Paul Sloan; Eduardo Bruera Journal: J Clin Oncol Date: 2016-07-25 Impact factor: 44.544
Authors: Dawn L Hershman; Christina Lacchetti; Robert H Dworkin; Ellen M Lavoie Smith; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Patrick Gavin; Antoinette Lavino; Maryam B Lustberg; Judith Paice; Bryan Schneider; Mary Lou Smith; Tom Smith; Shelby Terstriep; Nina Wagner-Johnston; Kate Bak; Charles L Loprinzi Journal: J Clin Oncol Date: 2014-04-14 Impact factor: 44.544
Authors: Marieke H J van den Beuken-van Everdingen; Laura M J Hochstenbach; Elbert A J Joosten; Vivianne C G Tjan-Heijnen; Daisy J A Janssen Journal: J Pain Symptom Manage Date: 2016-04-23 Impact factor: 3.612